Evidence map›Paper›PMID 38591107›Full record

ArticleACR open rheumatology2024

Patient-Led Urate Self-Monitoring to Improve Clinical Outcomes in People With Gout: A Feasibility Study.

Toni J F Michael, Daniel F B Wright, Jian S Chan, Matthew J Coleshill, Parisa Aslani, Dyfrig A Hughes, Richard O Day, Sophie L Stocker

Abstract read
In one paragraph

Article in ACR open rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. The experiences and perspectives of people with gout on urate self-monitoring.Health expectations : an international journal of public participation in health care and health policy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Toni J F MichaelSchool of Pharmacy, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia.ORCID https://orcid.org/0000-0002-6422-8683
Daniel F B WrightSchool of Pharmacy, University of Otago, Dunedin, New Zealand.ORCID https://orcid.org/0000-0001-9313-9252
Jian S ChanSt. Vincent's Clinical Campus, Faculty of Medicine, University of New South Wales, Sydney, Australia.ORCID https://orcid.org/0000-0002-4479-7926
Matthew J ColeshillBlack Dog Institute, Faculty of Medicine, University of New South Wales, Randwick, Australia.ORCID https://orcid.org/0000-0003-1906-1893
Parisa AslaniSchool of Pharmacy, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia.ORCID https://orcid.org/0000-0002-7976-8236
Dyfrig A HughesSchool of Medical and Health Sciences, Bangor University, Bangor, United Kingdom.ORCID https://orcid.org/0000-0001-8247-7459
Richard O DaySt. Vincent's Clinical Campus, Faculty of Medicine, University of New South Wales, Sydney, Australia, and Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Darlinghurst, Australia.ORCID https://orcid.org/0000-0002-6045-6937
Sophie L StockerSchool of Pharmacy, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia, and Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Darlinghurst, Australia.ORCID https://orcid.org/0000-0002-2114-587X

Funding

Arthritis Australia National Research Program Grant 2021
6 · The paper itself

Abstract

objectiveSelf-monitored point-of-care urate-measuring devices are an underexplored strategy to improve adherence to urate-lowering therapy and clinical outcomes in gout. This study observed patient-led urate self-monitoring practice and assessed its influence on allopurinol adherence, urate control, and health-related quality of life.

methodsPeople with gout (n = 31) and prescribed allopurinol self-monitored their urate concentrations (HumaSens2.0

resultsMost participants were male (94%) and had urate concentrations below the target (74%) at baseline. Overall, seven participants demonstrated repeated periods of "missed doses" (two or fewer allopurinol doses missed consecutively) and "drug holidays" (three or more missed doses). Most participants (94%) persisted with allopurinol. Time spent within the target urate concentration increased 1.3-fold (from 79% to 100%; P = 0.346), and the incidence of gout flares decreased 1.6-fold (from 8 to 5; P = 0.25) in the final quarter compared to that in the first quarter of the study. Health-related quality of life was reduced for participants reporting at least one gout flare (median utility values 0.9309 vs 0.9563, P = 0.04).

conclusionPatient-led urate self-monitoring may support the maintenance of allopurinol adherence and improve urate control, thus reducing the incidence of gout flares. Further research on patient-led urate self-monitoring in a randomized controlled study is warranted.

Identifiers

PMID38591107
PMCPMC11246832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.